Skip to main content
. 2016 Oct 18;2016:8254797. doi: 10.1155/2016/8254797

Figure 7.

Figure 7

Treatment with IL-22R1 antibody ameliorated the protective role of IL-22 in LPC-, glucose-, or combination-treated HUVECs. Cells were treated with LPC (10 μg/mL), glucose (30 mM), or a combination of the two (10 μg/mL LPC + 30 mM glucose) for 12 h followed by incubation with 40 ng/mL IL-22 or 0.8 μg/mL IL-22R1 antibody + 40 ng/mL IL-22 for 24 h. IL-22R1 antibody (8 μg/mL) was added 1 h before treatment with 40 ng/mL IL-22. The apoptotic rate was quantified by flow cytometry. Data shown represent mean ± SEM of three independent experiments. && P < 0.01 versus control group; &&& P < 0.0001 versus control group. # P < 0.05 versus IL-22-treated group; ## P < 0.01 versus IL-22 treated group; ### P < 0.0001 versus IL-22 treated group.